<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653848</url>
  </required_header>
  <id_info>
    <org_study_id>SPCG-13</org_study_id>
    <secondary_id>2006-001657-94</secondary_id>
    <nct_id>NCT00653848</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy</brief_title>
  <acronym>AdRad</acronym>
  <official_title>Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scandinavian Prostate Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Prostate Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour&#xD;
      burden it should be effective in primarily treated intermediate and high risk prostate cancer&#xD;
      as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be&#xD;
      tested in a randomised phase III trial where patients will be randomized either to docetaxel&#xD;
      or surveillance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:&#xD;
&#xD;
        -  PSA progression rate, ASTRO guidelines.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  PSA doubling time after progression&#xD;
&#xD;
        -  Quality of Life (QoL)&#xD;
&#xD;
        -  Safety&#xD;
&#xD;
        -  Metastases free survival&#xD;
&#xD;
        -  Overall survival&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA progression rate</measure>
    <time_frame>From randomization to progression</time_frame>
    <description>According to RTOG-ASTRO guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA doubling time after progression, quality of life, safety, metastases free survival, overall survival</measure>
    <time_frame>From randomisation to year 2014</time_frame>
    <description>PSA doubling measured, FACT-P, detection of metastatic lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>six of docetaxel every third week + hormonal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>hormonal treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 75 mg/square meter i.v. every third week, six cycles</description>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <other_name>LHRH ananlog 9 months</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men &gt; 18 and â‰¤75 years of age.&#xD;
&#xD;
          -  WHO/ECOG performance status 0 - 1.&#xD;
&#xD;
          -  Histological proven adenocarcinoma of the prostate within 12 months prior to&#xD;
             randomisation&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  T2 with Gleason score 7(4+3 ) and PSA &gt;10 ng/ml to &lt; 70 ng/ml&#xD;
&#xD;
               -  T2 with Gleason 8-10, any PSA &lt; 70 ng/ml&#xD;
&#xD;
               -  any T3 tumour&#xD;
&#xD;
          -  Prior neoadjuvant hormone therapy is mandatory for all patients&#xD;
&#xD;
          -  Adequate haematological-, liver- and kidney function. (Hemoglobin &gt; 110 g/l,&#xD;
             neutrophils &gt; 1.5 x 109/ l, platelets &gt; 150 x 109/ l, ASAT and ALAT &lt; 1.5 x ULN, ALP &lt;&#xD;
             1.5 x ULN, creatinine &lt; 1.5 x ULN)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  M+&#xD;
&#xD;
          -  N+ clinical or pathological&#xD;
&#xD;
          -  Patients with a history of previous malignant disease. Exceptions should be made for&#xD;
             basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should&#xD;
             also be made for curatively treated malignant disease, which has been disease free for&#xD;
             the past five years.&#xD;
&#xD;
          -  Previous radiotherapy to the pelvic region.&#xD;
&#xD;
          -  Previous chemotherapy within 5 years.&#xD;
&#xD;
          -  Systemic corticosteroids within 6 months prior to randomisation.&#xD;
&#xD;
          -  Unstable cardiovascular disease, including myocardial infarction, within 6 months&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  Active untreated infectious disease, including tuberculosis, MRSA.&#xD;
&#xD;
          -  Active gastric ulcer.&#xD;
&#xD;
          -  Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel)&#xD;
&#xD;
          -  Other serious illness or medical condition&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirkko-Liisa i Kellokumpu-Lehtinen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jon R Iversen</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant treatment, high risk, radical radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

